Kereiakes DJ - Search Results

1

Efficacy and safety of alirocumab in patients with or without prior coronary revascularization: Pooled analysis of eight ODYSSEY phase 3 trials.

Kereiakes DJ, Lepor NE, Gerber R, Veronica Lee L, Elassal J, Thompson D, Michael Gibson C. Kereiakes DJ, et al. Atherosclerosis. 2018 Oct;277:211-218. doi: 10.1016/j.atherosclerosis.2018.07.010. Epub 2018 Jul 10. Atherosclerosis. 2018. PMID: 30025648 Free article.

2

Effective and efficient strategies for coronary revascularization in the drug-eluting stent era.

Lepor NE, Madyoon H, Kereiakes D. Lepor NE, et al. Rev Cardiovasc Med. 2002;3 Suppl 5:S38-50. Rev Cardiovasc Med. 2002. PMID: 12478234 Review.

3

Therapeutic goals for effective platelet inhibition: a consensus document.

Wiviott SD, Michelson AD, Berger PB, Lepor NE, Kereiakes DJ. Wiviott SD, et al. Among authors: kereiakes dj. Rev Cardiovasc Med. 2006 Fall;7(4):214-25. Rev Cardiovasc Med. 2006. PMID: 17224865 Review.

4

Contemporary issues in the cath lab. Introduction.

Kereiakes DJ, Lepor NE. Kereiakes DJ, et al. Rev Cardiovasc Med. 2006;7 Suppl 4:S1-2. Rev Cardiovasc Med. 2006. PMID: 17224885 No abstract available.

5

Ischemia is the critical determinant of revascularization benefit: an interventionalist's perspective of the COURAGE trial.

Kereiakes DJ. Kereiakes DJ. Rev Cardiovasc Med. 2009;10 Suppl 2:S45-52. doi: 10.3909/ricm10S20006. Rev Cardiovasc Med. 2009. PMID: 19898281 Review.

6

Risk stratification and timing of revascularization: which patients benefit from early versus later revascularization?

Sarembock IJ, Kereiakes DJ. Sarembock IJ, et al. Among authors: kereiakes dj. Curr Cardiol Rep. 2012 Aug;14(4):510-20. doi: 10.1007/s11886-012-0279-5. Curr Cardiol Rep. 2012. PMID: 22581166 Review.

7

Reassessing the importance of complete versus incomplete coronary revascularization.

Kereiakes DJ. Kereiakes DJ. Rev Cardiovasc Med. 2014;15(1):24-30. doi: 10.3909/ricm0714. Rev Cardiovasc Med. 2014. PMID: 24762463 Review.

8

Effect of alirocumab, a monoclonal proprotein convertase subtilisin/kexin 9 antibody, on lipoprotein(a) concentrations (a pooled analysis of 150 mg every two weeks dosing from phase 2 trials).

Gaudet D, Kereiakes DJ, McKenney JM, Roth EM, Hanotin C, Gipe D, Du Y, Ferrand AC, Ginsberg HN, Stein EA. Gaudet D, et al. Among authors: kereiakes dj. Am J Cardiol. 2014 Sep 1;114(5):711-5. doi: 10.1016/j.amjcard.2014.05.060. Epub 2014 Jun 18. Am J Cardiol. 2014. PMID: 25060413 Free article. Clinical Trial.

9

Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins: rationale and design of the ODYSSEY COMBO I and II trials.

Colhoun HM, Robinson JG, Farnier M, Cariou B, Blom D, Kereiakes DJ, Lorenzato C, Pordy R, Chaudhari U. Colhoun HM, et al. Among authors: kereiakes dj. BMC Cardiovasc Disord. 2014 Sep 20;14:121. doi: 10.1186/1471-2261-14-121. BMC Cardiovasc Disord. 2014. PMID: 25240705 Free PMC article. Clinical Trial.

10

The potential role of anti-PCSK9 monoclonal antibodies in the management of hypercholesterolemia.

Lepor NE, Contreras L, Desai C, Kereiakes DJ. Lepor NE, et al. Among authors: kereiakes dj. Rev Cardiovasc Med. 2014;15(4):290-307; quiz 308-9. doi: 10.3909/ricm0773. Rev Cardiovasc Med. 2014. PMID: 25662924 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

579 results

Search Page